Janux Therapeutics, Inc. financial data

Symbol
JANX on Nasdaq
Industry
Pharmaceutical Preparations
Location
10955 Vista Sorrento Parkway, Suite 200, San Diego, California
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.99K % +36.4%
Debt-to-equity 9.05 % -30.7%
Return On Equity -13.5 % +34.3%
Return On Assets -12.4 % +31.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.7M shares +23.5%
Common Stock, Shares, Outstanding 51.8M shares +24%
Entity Public Float 280M USD +36.5%
Common Stock, Value, Issued 51K USD +21.4%
Weighted Average Number of Shares Outstanding, Basic 49M shares +17.4%
Weighted Average Number of Shares Outstanding, Diluted 49M shares +17.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 53.1M USD -10.1%
General and Administrative Expense 27M USD +13.6%
Operating Income (Loss) -72.9M USD +1.32%
Nonoperating Income (Expense) 17.3M USD +157%
Net Income (Loss) Attributable to Parent -55.6M USD +17.2%
Earnings Per Share, Basic -1.2 USD/shares +25.9%
Earnings Per Share, Diluted -1.2 USD/shares +25.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 213M USD +601%
Accounts Receivable, after Allowance for Credit Loss, Current 519K USD -30.8%
Assets, Current 659M USD +105%
Property, Plant and Equipment, Net 6.52M USD -9.52%
Operating Lease, Right-of-Use Asset 20.5M USD -6.69%
Other Assets, Noncurrent 2.52M USD +56.7%
Assets 689M USD +95.2%
Accounts Payable, Current 2.25M USD +9.9%
Employee-related Liabilities, Current 1.33M USD -3.36%
Accrued Liabilities, Current 5.81M USD -24.9%
Contract with Customer, Liability, Current 972K USD -80.3%
Liabilities, Current 10.6M USD -34.2%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 22.6M USD -6.5%
Liabilities 33.2M USD -20.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -524K USD +29.1%
Retained Earnings (Accumulated Deficit) -184M USD -43.5%
Stockholders' Equity Attributable to Parent 656M USD +111%
Liabilities and Equity 689M USD +95.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.8M USD -6.66%
Net Cash Provided by (Used in) Financing Activities 322M USD +20291%
Net Cash Provided by (Used in) Investing Activities -114M USD -1201%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 51.8M shares +23.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 45M USD +45.2%
Deferred Tax Assets, Gross 52.6M USD +35.2%
Operating Lease, Liability 24.2M USD -5.31%
Depreciation 532K USD +17.4%
Payments to Acquire Property, Plant, and Equipment 197K USD -30.9%
Lessee, Operating Lease, Liability, to be Paid 34.1M USD -8.89%
Property, Plant and Equipment, Gross 9.96M USD +15.6%
Operating Lease, Liability, Current 1.57M USD +16%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.61M USD +3.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.51M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.92M USD -16.6%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.72M USD +2.99%
Deferred Tax Assets, Operating Loss Carryforwards 18.7M USD +15.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 2.39M USD +87.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.83M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 7.65M USD -3.67%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%